fruquintinib+sintilimab

Monoclonal antibody

fruquintinib+sintilimab is one of 44 small molecule programs targeting Renal Cell Carcinoma. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Renal Cell CarcinomaActive, not recruiting

Renal Cell CarcinomaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

363 competitors in Renal Cell Carcinoma

#DrugCompanyPhaseTrials

Cabometyx

Bristol-Myers Squibb

Phase 3

31 2

Nexavar

Bayer

Phase 3

23 3

Lenvima

Eisai

Phase 3

21 4

Inlyta

PPrism Pharmaceuticals

Phase 3

27 5

Tecentriq

Roche

Phase 3

8 6

Welireg

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

18 7

Imjudo

AstraZeneca

Phase 3

3 8

Imfinzi

AstraZeneca

Phase 3

2 9

Depo-Provera

Eli Lilly

Phase 3

1 10

TKI258

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Renal Cell Carcinoma1 trial

Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

Active, not recruiting·HHutchmed·Phase 2/3·NCT05522231·265 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for fruquintinib+sintilimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — fruquintinib+sintilimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for fruquintinib+sintilimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hutchmed company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Company: HHutchmed

fruquintinib+sintilimab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Renal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News